Objective. We sought to compare daptomycin with ceftriaxone for the treatment of patients with communityacquired pneumonia (CAP).
Daptomycin is rapidly bactericidal against gram-positive bacteria, including Staphylococcus aureus and Streptococcus pneumoniae [1] . In rats, daptomycin concentrations in the lung are 20%-30% of those in plasma during the first 4 h after administration but, after 4 h, exceed those in plasma (Cubist Pharmaceuticals, un-
PATIENTS AND METHODS
Study design. Study DAP-00-05 and Study DAP-CAP-00-08 were randomized, double-blind, comparative trials designed to evaluate the safety and efficacy of daptomycin for the treatment of patients with CAP. Both studies had similar designs, inclusion and exclusion criteria, study populations, and assessments. Study DAP-00-05 was conducted from October 2000 through September 2001 in Europe, the United States, Canada, Australia, New Zealand, and South Africa. Study DAP-CAP-00-08 was conducted from July 2001 through February 2002 in South America, Europe, Mexico, and South Africa. The studies were conducted in accordance with the Declaration of Helsinki and guidelines for studies involving human subjects. The protocols were approved by the ethical review board at each site.
Patient eligibility. Patients aged у18 years who had CAP requiring hospitalization and intravenous therapy for у5 days were eligible. Patients were required to have a new pulmonary infiltrate found on a chest radiograph within 48 h after enrollment and у2 of the following clinical characteristics: cough, purulent sputum or change in sputum character, rales or pulmonary consolidation, dyspnea or tachypnea, fever (oral temperature, 138.0ЊC) or hypothermia (core temperature, Patients were excluded if they had respiratory failure, severe pneumonia (defined as a Pneumonia Severity Index of V according to the methods of Fine et al. [5] ), severe shock, possible Legionella pneumonia, known or suspected tuberculosis, bacterial meningitis, nosocomial pneumonia, lung cancer or malignancy metastatic to lung, malignancy not in remission, induction chemotherapy within 2 weeks before enrollment or therapies expected to result in neutropenia (neutrophil count, ) or possible Pneumocystis jiroveci pneumonia, known bronchial obstruction or prior postobstructive pneumonia, cystic fibrosis, or a calculated creatinine clearance !30 mL/min. Patients were also excluded if they were likely to die within 48 h after receiving treatment, could not tolerate ceftriaxone or had a b-lactam allergy, needed 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor therapy, had received potentially effective antibacterial therapy for 124 h within 72 h before enrollment, had received prior daptomycin therapy, or were likely to need nonprotocol systemic antibiotics. Pregnant or nursing women were excluded.
Treatment. Patients received either intravenous daptomycin (4 mg/kg) or ceftriaxone (2 g) every 24 h. Patients with suspected or confirmed gram-negative infections may have received aztreonam. The duration of therapy was 5-14 days (at the discretion of the investigator) but could be extended.
Clinical and microbiological assessments. Clinical symptoms and signs were evaluated, and appropriate cultures were performed within 24 h before starting treatment, during therapy, up to 3 days after completing treatment, and 7-14 days after completing treatment (i.e., the test-of-cure visit). Safety assessments were conducted from the baseline visit to the final visit.
Clinical cure was defined as the absence or improvement of clinically significant symptoms and signs such that no additional therapy was required. Clinical response was defined as clinical failure if symptoms and signs persisted or progressed, the patient died, or the study therapy was stopped because of an adverse event.
Sputum specimens were sent for Gram staining, with acceptable specimens determined by microscopic examination. If the culture yielded a gram-positive pathogen (i.e., S. pneumoniae or S. aureus), specimens were sent for culture during the period of therapy until the culture result was negative. Bronchial brushings or transtracheal aspiration were performed if needed. Blood cultures were performed at baseline, at the test-of-cure visit, and as needed. Gram-positive pathogens were sent to central laboratories for confirmation and susceptibility testing by Kirby-Bauer disk diffusion and broth microdilution methods [6] [7] [8] . At the test-of-cure visit, microbiological success was defined as eradication or presumed eradication (for patients assessed as cured if no specimens were obtained) of all gram-positive pathogens isolated at baseline.
Statistical analysis. The enrolled population included all patients who were randomized. The safety population included patients who received у1 dose of study drug. The intent-totreat (ITT) population included patients with CAP who received у1 dose of study drug. The modified intent-to-treat (mITT) population included patients in the ITT population who had S. pneumoniae or S. aureus isolated from sputum or blood specimens at baseline. The clinically evaluable (CE) population included patients who received the correct study drug for у3 days, had the required clinical assessments, and did not receive any potentially effective therapy for 124 h (unless classified as having experienced treatment failure). The microbiologically evaluable (ME) population included patients in the CE population who had S. pneumoniae or S. aureus isolated at baseline.
The studies were designed to show that daptomycin was noninferior to ceftriaxone for the treatment of CAP. Primary and secondary efficacy variables from each study and from the pooled data were analyzed using 95% CIs for the difference in the success rates between the daptomycin and ceftriaxone arms, using normal approximations to the binomial distribution. The primary efficacy variables for each study were the clinical success rates at the test-of-cure visit among the ITT and CE populations. Noninferiority was defined as the lower limit of the 95% CI for the difference in success rates being greater than Ϫ10%. Statistical significance was defined as the 95% CI excluding zero. For additional analyses, Fisher's exact test was used to compare rates. Significance tests were 2-sided with . Logistic regression analyses were used to determine a p 0.05 whether possible risk factors influenced success rates [9] . For both studies, 252 clinically evaluable patients in each group were needed to result in 80% power to detect noninferiority.
RESULTS

Patients.
The numbers of the patients in each study population, after pooling the data from both studies, are shown in table 1. In the ITT population, 743 patients (89.0%) were treated for 5-14 days; only 19 patients (2.3%) received 114 days of therapy. A total of 349 daptomycin-treated patients (84.5%) and 395 ceftriaxone-treated patients (93.8%) completed therapy. The most common reasons for premature discontinuation of therapy were clinical failure (44 daptomycintreated patients and 23 ceftriaxone-treated patients) and adverse events (15 daptomycin-treated patients and 12 ceftriaxone-treated patients).
The demographic and clinical characteristics of the treatment groups were similar at baseline (table 2) . Concomitant aztreonam therapy, allowed by the protocol, was administered to 96 daptomycin-treated patients (23.2%) and 66 ceftriaxonetreated patients (15.7%; ). Thirteen daptomycin-P p .007 treated patients (3.1%) and 12 ceftriaxone-treated patients (2.9%) were excluded from the CE population, because they received potentially effective therapy against gram-positive organisms for 124 h prior to enrollment or for 148 h during therapy for reasons other than treatment failure.
In the ITT population, 132 and 116 patients in the daptomycin and ceftriaxone groups, respectively, had a gram-positive pathogen isolated at baseline; these patients constituted the mITT population (table 3) . Overall, S. pneumoniae was isolated from 81.0% of patients, including 14 patients from whom S. aureus was also isolated. Among isolates tested at the central laboratory, 83.8% of the S. pneumoniae isolates were penicillin susceptible, and 95.7% of the S. aureus isolates were methicillin susceptible. All of the isolates tested were susceptible to daptomycin, with MICs р0.5 mg/mL. Among S. pneumoniae isolates, the MIC 90 was 0.12 mg/mL (range, р0.03 to 0.5 mg/mL). Among S. aureus isolates, the MIC 90 was 0.25 mg/mL (range, 0.06-0.5 mg/mL). In the mITT population, 23.8% of patients had at least 1 positive blood culture result. The pathogen most frequently isolated from blood specimens was S. pneumoniae (89.8% of isolates).
Outcomes. In each study and for all populations examined, the clinical cure rates among daptomycin-treated patients were lower than the rates among ceftriaxone-treated patients. After combining the data from the studies, cure rates were significantly lower among daptomycin-treated patients in the ITT and CE populations but not among those in the mITT population (table 4) . Similar results were obtained in analyses of all randomized and all treated patients (data not shown). The cure rates among patients with positive blood culture results at baseline were 66.7% (20 of 30 patients) and 75.9% (22 of 29 patients) among daptomycin-treated and ceftriaxone-treated patients, respectively, in the mITT population (95% CI for the difference in cure rates, Ϫ32.2% to 13.8%). In addition, there was a positive association between increased severity of illness (assessed by the Pneumonia Severity Index) and poor clinical outcome among daptomycin-treated patients (data not shown).
Because most patients assessed as experiencing clinical cure did not typically have adequate follow-up blood or sputum cultures performed, microbiological responses were analyzed using combined documented and presumed eradication rates. In the pooled ME population, the S. pneumoniae eradication rate was significantly lower among daptomycin-treated patients than among ceftriaxone-treated patients; the differences in S. aureus eradication rates approached statistical significance (table 5). Two daptomycin-treated patients assessed as experiencing clinical cure had documented pathogen persistence in sputum specimens; 1 had persistence of S. pneumoniae, and 1 had persistence of S. aureus. No ceftriaxone-treated patient assessed as experiencing cure had documented pathogen persistence. Outcomes based on prior antimicrobial therapy. Although few patients received potentially effective therapy for 124 h within 72 h before enrollment (an exclusion criteria), analysis revealed that ∼50% of patients had received antibacterial therapy for !24 h. In a posthoc analysis to examine the effect of this treatment on outcome, prior effective therapy was defined as treatment with antibacterial agents with both greater potency and longer half-lives (e.g., levofloxacin, ceftriaxone, azithromycin, and clarithromycin). Patients who had not received antibacterial therapy or who received therapy with only agents with lesser potency or shorter half-lives (e.g., penicillins, tetracyclines, or trimethoprim-sulfamethoxazole) were classified as having not received prior effective therapy. Among patients in the pooled CE population who had not received prior effective therapy, the cure rate was significantly lower among daptomycin-treated patients than among ceftriaxone-treated patients (table 6) . However, among those who had received prior effective therapy, clinical cure rates were similar in both treatment groups. Outcomes among patients treated with penicillins (including ampicillin and amoxicillin) were similar to the outcomes among those who received no prior antibiotic therapy (data not shown). In Study DAP-00-05, among patients in the ME population with S. aureus or S. pneumoniae infections who had not received prior effective therapy, the clinical cure rates among daptomycin-treated and ceftriaxone-treated pa- .06 mg/mL, 0.12-1.0 mg/mL, and у2.0 mg/mL, respectively, and the MICs for ceftriaxone-susceptible, intermediate, and resistant isolates were р0.5 mg/mL, 1.0 mg/mL, and у2.0 mg/mL, respectively. tients were 78.8% (63 of 80 patients) and 91.7% (55 of 60 patients), respectively (95% CI for the difference between cure rates, Ϫ24.3% to Ϫ1.5%); among those who had received prior effective therapy, the cure rates were 84.6% (22 of 26 patients) and 89.7% (26 of 29 patients), respectively (95% CI for the difference between cure rates, Ϫ22.8% to 12.7%). Multivariate logistic regression analysis using pooled CE population data revealed that prior effective therapy was associated with a higher success rate only among daptomycin-treated patients (data not shown). Prior effective therapy also had an impact on the persistence of S. pneumoniae in sputum specimens on or after day 2 of study drug therapy. In Study DAP-00-05, among patients who had not received prior effective therapy, persistence was significantly more frequent among daptomycin-treated patients than among ceftriaxone-treated patients (table 7) . Among patients in both groups who received prior effective therapy, persistence of S. pneumoniae was uncommon. Among daptomycin-treated patients, rates of S. pneumoniae persistence on or after day 2 of therapy were significantly lower ( ) among P p .011 those who had received prior effective therapy (4.3%) than among those who had not received such therapy (31.9%). Among ceftriaxone-treated patients, the persistence rate among those who had received prior effective therapy was 0%, compared with 9.4% among those who had not received such therapy ( ). P p .317 Demographic characteristics were also examined for their potential impact on outcome. Among daptomycin-treated patients, cure rates appeared to be higher among patients enrolled at sites in Western Europe, North America, and South America than among patients enrolled in Eastern Europe, Australia, New Zealand, and South Africa, but the difference was not statistically significant ( ). These findings are likely to be at-P p .25 tributable to the fact that a disproportionate number of patients who received prior effective therapy were enrolled at sites in North America and Western Europe (data not shown).
Safety and tolerability. Although no clinically relevant differences in treatment-emergent adverse events were noted (ta- ble 8), more ceftriaxone-treated patients developed headaches, insomnia, dizziness, and abdominal pain, and more daptomycin-treated patients developed injection site phlebitis, chest pain, and herpes simplex virus infections. Nineteen daptomycin-treated patients (4.2%) and 15 ceftriaxone-treated patients (3.3%) discontinued study drug therapy because of an adverse event ( ). P p .489 Treatment-emergent elevations in creatine phosphokinase level (classified as adverse events) developed in 6 daptomycintreated patients (1.3%) and 6 ceftriaxone-treated patients (1.3%). None of the events were assessed as serious, and none of the patients had study drug therapy discontinued because of the elevation. The events resolved in 5 daptomycin-treated patients and 3 ceftriaxone-treated patients. Treatment-emergent elevations in creatine phosphokinase level to 11000 U/L that were not reported as adverse events developed in 4 daptomycintreated patients (0.9%) and 1 ceftriaxone-treated patient (0.2%). Among daptomycin-treated patients with elevations in creatine phosphokinase level, the level normalized in 2 patients, improved in 1, and remained elevated in 1. This last patient developed sepsis with renal and hepatic failure and died of respiratory failure on day 2 of therapy. No follow-up value was obtained for the ceftriaxone-treated patient.
Twenty-one daptomycin-treated patients (4.6%) and 12 ceftriaxone-treated patients (2.6%) died during the studies ( ); no death was assessed as study drug related. Causes P p .073 of death that occurred in у2 daptomycin-treated patients included respiratory failure ( ), chronic obstructive airway n p 5 disease exacerbation ( ), cardiac failure ( ), and carn p 3 n p 3 diac arrest ( ). Among ceftriaxone-treated patients, causes n p 2 of death included pulmonary embolism ( ), septic shock n p 3 ( ), worsening pneumonia ( ), and metastases to the n p 3 n p 2 brain or liver ( ). Including those who died, 62 dapton p 2 mycin-treated patients (13.6%) and 38 ceftriaxone-treated patients (8.3%) developed at least 1 serious adverse event. Most serious events were infections ( ), cardiac disorders n p 33 ( ), or respiratory disorders ( ). Only 3 serious n p 22 n p 18 events that occurred in the daptomycin-treated patients (coma, tachyarrhythmia, and respiratory failure) and 1 that occurred in the ceftriaxone-treated patients (neutropenia) were assessed as possibly related to study drug.
DISCUSSION
The pooled results of these 2 trials indicate that daptomycin was significantly less effective than ceftriaxone for the treatment of patients hospitalized with CAP. However, 170% of daptomycin-treated patients in the pooled ITT population were assessed as experiencing clinical cure, and the mortality rate was 4.6%. Among daptomycin-treated patients with S. pneumoniae CAP, the mortality rate was 2.8%. These results contrast with reported mortality rates for pneumonia, which were generally 20%-40% before antibiotic therapy [10] and, in 1 series, 37.7% among adult patients hospitalized with pneumococcal pneumonia [11] . Although comparisons with historical data should be interpreted with caution, the differences suggest that other factors impacted clinical outcome. It has been theorized that daptomycin efficacy in the lung may be related to disease pathology [4] . Daptomycin had little activity in a mouse model of broncheoaleveolar pneumonia but was active in a mouse inhalation anthrax model associated with extensive alveolar destruction and in a hamster lung infection model in which emphysematous changes were induced prior to lung infection [2, 4, 12] . Daptomycin was more effective than was either vancomycin or nafcillin in a rat model of hematogenous S. aureus pneumonia [4] . Similarly, a posthoc analysis from 1 clinical trial revealed that daptomycin was as efficacious as vancomycin for treating septic pulmonary emboli associated with right-sided endocarditis caused by methicillinresistant S. aureus, although the number of patients was small [13] .
Logistic regression analyses revealed that daptomycin-treated patients who had received up to 24 h of effective therapy before enrollment had higher success rates than did those who had not received such therapy. In both treatment groups, the S. pneumoniae persistence rates on or after day 2 of therapy were lower among those who had received prior effective therapy than among those who had not received prior effective therapy, although the difference was only statistically significant among daptomycin-treated patients. Thus, prior effective therapy may have impacted all patients.
The duration of prior effective therapy was ∼1 day. Although significantly shorter than durations generally used for the treatment of CAP requiring hospitalization, 1 day of effective therapy may be sufficient for treating some cases. Several studies have revealed that 3-or 5-day treatment courses of azithromycin and 5-day courses of gemifloxacin, levofloxacin, and telithromycin are effective for CAP [14] [15] [16] [17] [18] . In addition, a single high-dose formulation of azithromycin was at least as effective as a 7-day course of levofloxacin or extended-release clarithromycin [19, 20] . It is possible that a single dose of potent agents with relatively long half-lives could impact the clinical outcome of CAP.
These observations may be confounded by other factors. The antibacterial agents used prior to enrollment may have influenced outcome by treating pathogens other than gram-positive organisms, including Legionella species, other gram-negative bacteria, Mycoplasma pneumoniae, and Chlamydophila pneumoniae. However, patients were screened for Legionella pneumonia by a urine antigen test, and the number of patients with atypical pathogens should have been approximately equal in both treatment groups because of the randomized study design. In addition, higher clinical cure rates were noted among daptomycin-treated patients who had S. aureus or S. pneumoniae infections and who had received prior effective therapy than among those patients who had not received prior effective therapy. Finally, the duration of time from pneumonia onset to the initiation of therapy may have also impacted outcome. Data on symptom duration before enrollment were not collected.
In conclusion, data from both studies revealed that daptomycin was less efficacious than was ceftriaxone for CAP therapy. However, for patients who received the equivalent of 1 day of prior effective antibacterial therapy, the cure rates were similar in both treatment groups. Because 1 day of effective therapy may impact clinical outcome, trials designed to evaluate CAP treatments may need to exclude patients who have received any potentially effective therapy prior to enrollment. However, such a study requirement may not be feasible because of the current quality-of-care measures emphasizing early antibiotic therapy for CAP.
